Background: Cardiac output (CO) is a prognostic factor in pulmonary hypertension (PH). Right heart catheterisation using the direct Fick method or thermodilution (TD) is the reference technique for CO measurement. Impedance cardiography (IPc) is a known non-invasive method of measuring CO. Objectives: In our study, we assume that the measurement of CO by IPc using the PHYSIOFLOW® system is as accurate as TD or using the direct Fick method in patients with PH in group 1 or group 4. Methods: A total of 75 patients were enrolled in a prospective study carried out at the hypertension reference centre of Toulouse University Hospital. Right heart catheterisation was performed for the diagnosis or follow-up of the disease. CO was measured using the Fick method, TD, and IPc simultaneously. A Bland-Altman analysis was plotted. Results: CO was 5.7 ± 1.9 L/min as measured by the Fick method, 5.4 ± 1.5 L/min by TD, and 5.5 ± 1.7 L/min by IPc. The bias between CO measurements by IPc and the direct Fick method was 0.149 L/min (95% CI, –0.298 to 0.596). The bias between CO measurements by IPc and the TD method was –0.153 L/min (95% CI, –0.450 to 0.153). The correlation decreased with the more extreme CO values (< 3 L/min or > 7 L/min). A few factors changed the agreement between measurements (BMI or membership in group 4). Conclusion: To conclude, this study shows that the measurement of CO by IPc in PH patients is reliable compared to the direct Fick method and TD obtained by right heart catheterisation. This accuracy decreases for extreme CO values.

Keywords:
Pulmonary hypertension, Impedance cardiography, Cardiac output
1.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al: Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.
2.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(suppl 25):D34–D41.
3.
Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
4.
Swiston JR, Johnson SR, Granton JT: Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med 2010; 104: 1588–1607.
5.
Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
6.
Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al: Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546–2552.
7.
Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ: 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2016; 133:e694–e711.
8.
Myers J, Wong M, Adhikarla C, Boga M, Challa S, Abella J, et al: Cardiopulmonary and noninvasive hemodynamic responses to exercise predict outcomes in heart failure. J Card Fail 2013; 19: 101–107.
9.
Tonelli AR, Alnuaimat H, Li N, Carrie R, Mubarak KK: Value of impedance cardiography in patients studied for pulmonary hypertension. Lung 2011; 189: 369–375.
10.
Critchley LA, Critchley JA: A meta-analysis of studies using bias and precision statistics to compare cardiac output measurement techniques. J Clin Monit Comput 1999; 15: 85–91.
11.
Nishikawa T, Dohi S: Errors in the measurement of cardiac output by thermodilution. Can J Anaesth J Can Anesth 1993; 40: 142–153.
12.
Lador F, Hervé P, Bringard A, Günther S, Garcia G, Savale L, et al: Non-invasive determination of cardiac output in pre-capillary pulmonary hypertension. PLoS One 2015; 10:e0134221.
13.
Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, et al: Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535–541.
14.
Rich JD, Archer SL, Rich S: Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J 2013; 42: 125–133.
15.
Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr: Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999; 1: 7–21.
16.
Paz R, Mohiaddin RH, Longmore DB: Magnetic resonance assessment of the pulmonary arterial trunk anatomy, flow, pulsatility and distensibility. Eur Heart J 1993; 14: 1524–1530.
17.
Robertson MB, Köhler U, Hoskins PR, Marshall I: Quantitative analysis of PC MRI velocity maps: pulsatile flow in cylindrical vessels. Magn Reson Imaging 2001; 19: 685–695.
18.
Beerbaum P, Körperich H, Barth P, Esdorn H, Gieseke J, Meyer H: Noninvasive quantification of left-to-right shunt in pediatric patients: phase-contrast cine magnetic resonance imaging compared with invasive oximetry. Circulation 2001; 103: 2476–2482.
19.
Sageman WS, Riffenburgh RH, Spiess BD: Equivalence of bioimpedance and thermodilution in measuring cardiac index after cardiac surgery. J Cardiothorac Vasc Anesth 2002; 16: 8–14.
20.
Albert NM, Hail MD, Li J, Young JB: Equivalence of the bioimpedance and thermodilution methods in measuring cardiac output in hospitalized patients with advanced, decompensated chronic heart failure. Am J Crit Care 2004; 13: 469–479.
21.
Ebert TJ, Smith JJ, Barney JA, Merrill DC, Smith GK: The use of thoracic impedance for determining thoracic blood volume changes in man. Aviat Space Environ Med 1986; 57: 49–53.
22.
Barin E, Haryadi DG, Schookin SI, Westenskow DR, Zubenko VG, Beliaev KR, et al: Evaluation of a thoracic bioimpedance cardiac output monitor during cardiac catheterization. Crit Care Med 2000; 28: 698–702.
23.
Van De Water JM, Miller TW, Vogel RL, Mount BE, Dalton ML: Impedance cardiography: the next vital sign technology? Chest 2003; 123: 2028–2033.
24.
Yung GL, Fedullo PF, Kinninger K, Johnson W, Channick RN: Comparison of impedance cardiography to direct Fick and thermodilution cardiac output determination in pulmonary arterial hypertension. Congest Heart Fail 2004; 10(2 suppl 2): 7–10.
25.
Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M, Mettauer B, et al: A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the “direct” Fick method. Eur J Appl Physiol 2000; 82: 313–320.
26.
Panagiotou M, Vogiatzis I, Jayasekera G, Louvaris Z, Mackenzie A, Mcglinchey N, et al: Validation of impedance cardiography in pulmonary arterial hypertension. Clin Physiol Funct Imaging 2017, DOI: 10.1111/cpf.12408.
27.
Bour J, Kellett J: Impedance cardiography: a rapid and cost-effective screening tool for cardiac disease. Eur J Intern Med 2008; 19: 399–405.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.